{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:15:33Z","timestamp":1788282933623,"version":"build-2803163510"},"reference-count":51,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2022,4,1]]},"DOI":"10.1001\/jamaoncol.2021.7656","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T16:01:50Z","timestamp":1645113710000},"page":"579","source":"Crossref","is-referenced-by-count":49,"title":["Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor\u2013Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation"],"prefix":"10.1001","volume":"8","author":[{"given":"Gelareh","family":"Sadigh","sequence":"first","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Gray","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Sparano","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, The Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betina","family":"Yanez","sequence":"additional","affiliation":[{"name":"Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia F.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lava R.","family":"Timsina","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samilia","family":"Obeng-Gyasi","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Gareen","sequence":"additional","affiliation":[{"name":"Center for Statistical Sciences, Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W.","family":"Sledge","sequence":"additional","affiliation":[{"name":"Stanford Cancer Center Palo Alto, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Whelan","sequence":"additional","affiliation":[{"name":"Canadian Cancer Trials Group, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[{"name":"Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne I.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Wake Forest University Health Sciences, Winston Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth C.","family":"Carlos","sequence":"additional","affiliation":[{"name":"University of Michigan Comprehensive Cancer Center, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"coi210106r2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3322\/caac.21412","article-title":"Breast cancer statistics, 2017, racial disparity in mortality by state.","volume":"67","author":"DeSantis","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"coi210106r3","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1002\/cncr.29935","article-title":"Understanding and effectively addressing breast cancer in African American women: unpacking the social context.","volume":"122","author":"Williams","year":"2016","journal-title":"Cancer"},{"issue":"22","key":"coi210106r4","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1093\/jnci\/93.22.1704","article-title":"Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys.","volume":"93","author":"Breen","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"coi210106r5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S1049-3867(02)00145-7","article-title":"Race, ethnicity, and disparities in breast cancer: victories and challenges.","volume":"12","author":"Bickell","year":"2002","journal-title":"Womens Health Issues"},{"issue":"24","key":"coi210106r6","doi-asserted-by":"publisher","first-page":"6100","DOI":"10.1158\/1078-0432.CCR-10-1533","article-title":"Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.","volume":"16","author":"O\u2019Brien","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"coi210106r7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/jnci\/djy136","article-title":"Endocrine therapy nonadherence and discontinuation in Black and White women.","volume":"111","author":"Wheeler","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"coi210106r8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer.","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"coi210106r9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/jnci\/djaa148","article-title":"Race, ethnicity, and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx Trial.","volume":"113","author":"Albain","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"coi210106r10","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer.","volume":"28","author":"Burstein","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"coi210106r11","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1200\/JCO.2010.33.3179","article-title":"Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer.","volume":"29","author":"Neugut","year":"2011","journal-title":"J Clin Oncol"},{"issue":"27","key":"coi210106r12","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","article-title":"Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.","volume":"28","author":"Hershman","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi210106r13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.24691","article-title":"Disparities in medical care among commercially insured patients with newly diagnosed breast cancer: opportunities for intervention.","volume":"116","author":"Short","year":"2010","journal-title":"Cancer"},{"issue":"11","key":"coi210106r14","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Differences in treatment patterns for localized breast carcinoma among Asian\/Pacific Islander women.","volume":"95","author":"Prehn","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"coi210106r15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1200\/JCO.2011.36.8399","article-title":"Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers.","volume":"30","author":"Wu","year":"2012","journal-title":"J Clin Oncol"},{"issue":"14","key":"coi210106r16","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1002\/cncr.v127.14","article-title":"Breast cancer patients\u2019 insurance status and residence zip code correlate with early discontinuation of endocrine therapy: an analysis of the ECOG-ACRIN TAILORx trial.","volume":"127","author":"Sadigh","year":"2021","journal-title":"Cancer"},{"issue":"21","key":"coi210106r17","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer.","volume":"373","author":"Sparano","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"coi210106r18","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer.","volume":"380","author":"Sparano","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"coi210106r21","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","article-title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.","volume":"25","author":"Hudis","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi210106r22","first-page":"1263","article-title":"The association between molecular subtypes of breast cancer with histological grade and lymph node metastases in Indonesian woman.","volume":"19","author":"Setyawati","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"coi210106r23","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.3892\/ol","article-title":"21-Gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes.","volume":"18","author":"Wang","year":"2019","journal-title":"Oncol Lett"},{"issue":"5","key":"coi210106r24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/jnci\/djr543","article-title":"Race and hormone receptor\u2013positive breast cancer outcomes in a randomized chemotherapy trial.","volume":"104","author":"Sparano","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"coi210106r25","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00059","article-title":"Impact of genetic ancestry on outcomes in ECOG-ACRIN-E5103.","volume":"2017","author":"Schneider","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"14","key":"coi210106r26","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/jnci\/djp175","article-title":"Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.","volume":"101","author":"Albain","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"coi210106r27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10 years.","volume":"375","author":"Goss","year":"2016","journal-title":"N Engl J Med"},{"issue":"17","key":"coi210106r28","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"coi210106r29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.13973","article-title":"Association of endocrine therapy with overall survival in women with small, hormone receptor-positive, ERBB2-negative breast cancer.","volume":"3","author":"Ma","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"8","key":"coi210106r30","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1001\/jamaoncol.2021.1693","article-title":"Association of modifiable risk factors with early discontinuation of adjuvant endocrine therapy: a post hoc analysis of a randomized clinical trial.","volume":"7","author":"Yanez","year":"2021","journal-title":"JAMA Oncol"},{"issue":"9187","key":"coi210106r31","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0140-6736(98)11392-2","article-title":"Influence of psychological response on survival in breast cancer: a population-based cohort study.","volume":"354","author":"Watson","year":"1999","journal-title":"Lancet"},{"issue":"7","key":"coi210106r32","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/bjc.2013.116","article-title":"Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality.","volume":"108","author":"Makubate","year":"2013","journal-title":"Br J Cancer"},{"issue":"6","key":"coi210106r33","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/tbj.12185","article-title":"Commercial insurance triples chances of breast cancer survival in a public hospital.","volume":"19","author":"Shi","year":"2013","journal-title":"Breast J"},{"issue":"1","key":"coi210106r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2019.100505","article-title":"Insurance status is related to overall survival in patients with small intestine adenocarcinoma: a population-based study.","volume":"44","author":"Wang","year":"2020","journal-title":"Curr Probl Cancer"},{"issue":"1","key":"coi210106r35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/CA.2007.0011","article-title":"Association of insurance with cancer care utilization and outcomes.","volume":"58","author":"Ward","year":"2008","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"coi210106r36","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/JCO.20.02602","article-title":"Persistent disparity: socioeconomic deprivation and cancer outcomes in patients treated in clinical trials.","volume":"39","author":"Unger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi210106r37","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.healthplace.2012.03.005","article-title":"Neighborhood deprivation and clinical outcomes among head and neck cancer patients.","volume":"18","author":"Reitzel","year":"2012","journal-title":"Health Place"},{"issue":"2","key":"coi210106r38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1158\/1055-9965.EPI-20-1055","article-title":"Neighborhood social environmental factors and breast cancer subtypes among Black somen.","volume":"30","author":"Qin","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"coi210106r39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1158\/1055-9965.EPI-20-1038","article-title":"Neighborhood-level redlining and lending bias are associated with breast cancer mortality in a large and diverse metropolitan area.","volume":"30","author":"Collin","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"coi210106r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.113738","article-title":"How are social determinants of health integrated into epigenetic research? a systematic review.","volume":"273","author":"Evans","year":"2021","journal-title":"Soc Sci Med"},{"issue":"4","key":"coi210106r41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/1099800412455688","article-title":"A systematic review of allostatic load, health, and health disparities.","volume":"14","author":"Beckie","year":"2012","journal-title":"Biol Res Nurs"},{"issue":"5","key":"coi210106r42","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3934\/publichealth.2017.5.526","article-title":"Black-White disparities in breast cancer subtype: the intersection of socially patterned stress and genetic expression.","volume":"4","author":"Linnenbringer","year":"2017","journal-title":"AIMS Public Health"},{"issue":"5","key":"coi210106r43","doi-asserted-by":"publisher","first-page":"826","DOI":"10.2105\/AJPH.2004.060749","article-title":"\u201cWeathering\u201d and age patterns of allostatic load scores among Blacks and Whites in the United States.","volume":"96","author":"Geronimus","year":"2006","journal-title":"Am J Public Health"},{"issue":"12","key":"coi210106r44","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.jacr.2020.10.017","article-title":"Biology of discrimination.","volume":"17","author":"Obeng-Gyasi","year":"2020","journal-title":"J Am Coll Radiol"},{"key":"coi210106r45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/nyas.1998.840.issue-1","article-title":"Stress, adaptation, and disease: allostasis and allostatic load.","volume":"840","author":"McEwen","year":"1998","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"coi210106r46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41523-021-00309-6","article-title":"Allostatic load: a framework to understand breast cancer outcomes in Black women.","volume":"7","author":"Obeng-Gyasi","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"coi210106r47","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s10549-021-06102-0","article-title":"Allostatic score and its associations with demographics, healthy behaviors, tumor characteristics, and mitochondrial DNA among breast cancer patients.","volume":"187","author":"Zhao","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"coi210106r48","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/1055-9965.EPI-19-0712","article-title":"Prediagnostic allostatic load as a predictor of poorly differentiated and larger sized breast cancers among Black women in the Women\u2019s Circle of Health Follow-up Study.","volume":"29","author":"Xing","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"coi210106r49","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.2147\/OTT","article-title":"ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy.","volume":"10","author":"Song","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"3","key":"coi210106r50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s12282-019-01029-3","article-title":"Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.","volume":"27","author":"Kawaguchi","year":"2020","journal-title":"Breast Cancer"},{"key":"coi210106r51","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2105\/AJPH.2014.302490","article-title":"Racial\/ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review.","volume":"105","author":"Roberts","year":"2015","journal-title":"Am J Public Health"},{"key":"coi210106r1","unstructured":"American Cancer Society. Key statistics for cancer: how common is breast cancer? 2022. Accessed June 3, 2021. https:\/\/www.cancer.org\/cancer\/breast-cancer\/about\/how-common-is-breast-cancer.html"},{"key":"coi210106r19","unstructured":"Agency for Healthcare Research and Quality. Chapter 3: creation of new race-ethnicity codes and SES indicators for Medicare beneficiaries\u2014chapter 3. January 2008. Accessed January 10, 2022. https:\/\/archive.ahrq.gov\/research\/findings\/final-reports\/medicareindicators\/medicareindicators3.html"},{"key":"coi210106r20","unstructured":"Health Resources & Services Administration. July 31, 2021. Accessed June 19, 2020. Area Health Resources Files. https:\/\/data.hrsa.gov\/topics\/health-workforce\/ahrf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2789162\/jamaoncology_sadigh_2022_oi_210106_1650482091.26181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T17:36:20Z","timestamp":1700242580000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2789162"}},"subtitle":["A Post Hoc Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2021.7656","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}